Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ramon V Tiu

Showing results (81-90 of 85) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 85 results.
Journal of Hematology & Oncology|November 29, 2013
Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet countsMoshe Talpaz, Ronald Paquette, Lawrence Afrin, et al.
Molecular Cancer Therapeutics|October 25, 2019
A Phase I Study of LY3009120, a Pan-RAF Inhibitor, in Patients with Advanced or Metastatic CancerRyan J Sullivan, Antoine Hollebecque, Keith T Flaherty, et al.
Molecular Cancer Therapeutics|November 21, 2019
ERK Inhibitor LY3214996 Targets ERK Pathway-Driven Cancers: A Therapeutic Approach Toward Precision MedicineShripad V Bhagwat, William T McMillen, Shufen Cai, et al.
Blood|March 15, 2014
Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasmsSa A Wang, Robert P Hasserjian, Patricia S Fox, et al.
Cell Reports|June 20, 2020
Low-Dose Vertical Inhibition of the RAF-MEK-ERK Cascade Causes Apoptotic Death of KRAS Mutant CancersIrem Ozkan-Dagliyan, J Nathaniel Diehl, Samuel D George, et al.
Pageof 9

Showing results (81-90 of 85) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 85 results.
Journal of Hematology & Oncology|November 29, 2013
Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet countsMoshe Talpaz, Ronald Paquette, Lawrence Afrin, et al.
Molecular Cancer Therapeutics|October 25, 2019
A Phase I Study of LY3009120, a Pan-RAF Inhibitor, in Patients with Advanced or Metastatic CancerRyan J Sullivan, Antoine Hollebecque, Keith T Flaherty, et al.
Molecular Cancer Therapeutics|November 21, 2019
ERK Inhibitor LY3214996 Targets ERK Pathway-Driven Cancers: A Therapeutic Approach Toward Precision MedicineShripad V Bhagwat, William T McMillen, Shufen Cai, et al.
Blood|March 15, 2014
Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasmsSa A Wang, Robert P Hasserjian, Patricia S Fox, et al.
Cell Reports|June 20, 2020
Low-Dose Vertical Inhibition of the RAF-MEK-ERK Cascade Causes Apoptotic Death of KRAS Mutant CancersIrem Ozkan-Dagliyan, J Nathaniel Diehl, Samuel D George, et al.
Pageof 9